NEW YORK, Aug. 31 /PRNewswire/ — Reportlinker.com announces
that a new market research report is available in its
catalogue:
The Global Orthobiologics Market – Players, products and
technologies driving change 2008
http://www.reportlinker.com/p0192725/The-Global-Orthobiologics-Market—Players-products-and-technologies-driving-change-2008.html
The primary advantage of synthetic bone graft substitutes and
growth factors compared with allograft bone tissue is that they do
not depend on the availability of donated human tissue. In
addition, owing to the potential risk of disease transmission,
synthetic materials and growth factors may be perceived as safer
than allograft-based bone tissue. Many new composite products are
also becoming available which seek to harness the combined
characteristics of synthetic and natural materials in one single
product optimised for rapid bone repair and regeneration.
Stem cell therapy is also showing huge potential as an
alternative to autograft. Mesenchymal stem cells (MSCs) found in
bone marrow, can form a variety of cells in the laboratory,
including fat cells, cartilage, bone, tendon and ligaments, muscles
cells, skin cells and even nerve cells. Unlike most other human
adult stem cells, MSCs can be obtained in quantities appropriate
for clinical applications, making them good candidates for use in
tissue repair. They also offer the advantage of low morbidity and
cost.
The last twelve months has seen consolidation in the
orthobiologic sector, although most of the acquisitions have been
relatively small in terms of money. The largest acquisition
‘/>”/>
SOURCE